中国医学前沿杂志（电子版）2024，Vol.16Issue(7)：1-21,21.DOI:10.12037/YXQY.2024.07-01
食管癌免疫检查点抑制剂临床应用全程管理专家共识
Expert consensus on the whole-process management of clinical application of immune checkpoint inhibitors for esophageal cancer
中国抗癌协会食管肿瘤整合康复专业委员会 1陈小兵1
作者信息
摘要
Abstract
With the rapid development in the field of tumor immunotherapy,immune checkpoint inhibitors(ICIs)centered on programmed death-1(PD-1)and programmed death ligand-1(PD-L1)have made significant progress in the treatment of esophageal cancer.Several studies have confirmed the effectiveness and safety of ICIs in the treatment of esophageal cancer,and have gradually changed the landscape for treating advanced esophageal cancer.At present,ICIs have been widely used in the clinical treatment of esophageal cancer in China.In order to better guide the whole-process management of esophageal cancer ICIs application,improve the scientificity and standardization of esophageal cancer ICIs application,the China Anti-cancer Association Esophageal Tumor Integration Rehabilitation Professional Committee organized domestic experts in related fields to systematically sort out the latest domestic and foreign guidelines and evidence-based medical evidence through multiple rounds of discussions and revisions,and reach a consensus among expert in this review by fully considered the specific situation of clinical practice in China.关键词
食管癌/免疫检查点抑制剂/全程管理/专家共识Key words
Esophageal cancer/Immune checkpoint inhibitor/Whole-process management/Expert consensus引用本文复制引用
中国抗癌协会食管肿瘤整合康复专业委员会,陈小兵..食管癌免疫检查点抑制剂临床应用全程管理专家共识[J].中国医学前沿杂志（电子版）,2024,16(7):1-21,21.
